Opens in a new tab
Monday, 16 November 2026
EVIDENCE. INTERPRETED.
Pharmacally

Disease & Drugs

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Disease & Drugs

1,785 stories · every one Fact-Checked
Acumen Pharmaceuticals' sabirnetug antibody fails to demonstrate clinical benefit despite amyloid plaque reduction in Phase 2 ALTITUDE-AD trial.Clinical TrialsAcumen Reports Sabirnetug Failure Despite Amyloid ReductionAcumen Pharmaceuticals reported that sabirnetug (ACU193) failed to demonstrate clinical benefit in the Phase 2 ALTITUDE-AD trial at either dose, despite significant amyloid plaque reduction.30 Oct 2026 · 4 min read
Fact-Checked
Alnylam's investigational RNAi therapy brezosiran demonstrates dose-dependent mutant huntingtin reduction in a Phase 1b Huntington's disease study.Clinical TrialsAlnylam’s Brezosiran Lowers Mutant Huntingtin by Up to 64%Alnylam’s investigational RNAi therapeutic brezosiran demonstrated dose-dependent mutant huntingtin reduction in its Phase 1b Huntington’s disease study, with mean reductions of 60–64% in the highest dose group at…30 Oct 2026 · 5 min read
Fact-Checked
ILUMYA (tildrakizumab) FDA approval for active psoriatic arthritis following Phase 3 INSPIRE-1 and INSPIRE-2 trials.New Drug ApprovalSun’s ILUMYA Gains New FDA Indication Following INSPIRE TrialsSun Pharma’s ILUMYA (tildrakizumab) has received FDA approval for adults with active psoriatic arthritis, expanding its use beyond plaque psoriasis.30 Oct 2026 · 4 min read
Fact-Checked
Geron's imetelstat development in a Phase 3 clinical trial for relapsed or refractory myelofibrosis.Clinical TrialsGeron Discontinues IMpactMF Trial After DMC Flags OS Endpoint RiskGeron has discontinued its Phase 3 IMpactMF trial evaluating imetelstat in relapsed or refractory myelofibrosis after an independent Data Monitoring Committee concluded that the study was unlikely to…30 Oct 2026 · 4 min read
Fact-Checked
OSE Immunotherapeutics Tedopi combination therapy Phase 2 trial survival results in metastatic non-small cell lung cancerClinical TrialsOSE’s Tedopi Shows Encouraging Survival Results in NSCLC TrialOSE Immunotherapeutics reported one-year overall survival rates of 47% and 46% with Tedopi plus docetaxel and Tedopi plus nivolumab, respectively, in the Combi-TED Phase 2 trial.30 Oct 2026 · 4 min read
Fact-Checked
Efzofitimod Phase 3 EFZO-FIT trial results in pulmonary sarcoidosis reported by aTyr PharmaClinical TrialsaTyr’s Efzofitimod Shows Mixed Results in SarcoidosisaTyr Pharma’s Phase 3 EFZO-FIT trial failed to demonstrate a significant steroid-sparing benefit for efzofitimod in pulmonary sarcoidosis.29 Oct 2026 · 4 min read
Fact-Checked
CervoMed’s neflamapimod Phase 2b trial results in dementia with Lewy bodiesClinical TrialsCervoMed Reports Mixed Findings for Neflamapimod in DLBCervoMed’s Phase 2b RewinD-LB trial failed to confirm neflamapimod’s primary CDR-SB endpoint in dementia with Lewy bodies.29 Oct 2026 · 5 min read
Fact-Checked
Minimalist medical illustration of oral GLP-1 receptor agonist research showing glucose regulation and body weight reduction in type 2 diabetes.Clinical TrialsAscletis’ Oral ASC30 Delivers Up to 1.7% HbA1c ReductionAscletis Pharma reported placebo-adjusted HbA1c reductions of 1.6% to 1.7% with oral GLP-1 receptor agonist ASC30 in a 13-week Phase II type 2 diabetes study.29 Oct 2026 · 4 min read
Fact-Checked
ONO-1110 Phase 2 clinical studies evaluating an investigational endocannabinoid modulator for chronic pain conditions.Clinical TrialsOno Advances ONO-1110 Despite Failed Pain Trial EndpointsOno Pharmaceutical plans further clinical studies of ONO-1110 in postherpetic neuralgia, fibromyalgia and Hunner-type interstitial cystitis after exploratory pain-score signals emerged in Phase 2 analyses.29 Oct 2026 · 4 min read
Fact-Checked
HUTCHMED SAFFRON Phase III trial shows improved survival with savolitinib plus osimertinib in EGFR-mutated non-small cell lung cancer.Clinical TrialsHUTCHMED’s SAFFRON Shows Benefit from Adding Savolitinib After Osimertinib FailureHUTCHMED’s global Phase III SAFFRON trial demonstrated significant improvements in progression-free and overall survival with savolitinib plus osimertinib versus platinum-based chemotherapy in patients with EGFR-mutated NSCLC and high…29 Oct 2026 · 4 min read
Fact-Checked
Illustration of dual EGFR and MET inhibition with osimertinib and savolitinib in EGFR-mutated, MET-overexpressing non-small cell lung cancerClinical TrialsHUTCHMED Reports 24.9-Month PFS With First-Line Savolitinib CombinationHUTCHMED’s Phase III SANOVO trial found that savolitinib plus osimertinib extended median progression-free survival by 11.1 months versus osimertinib alone in previously untreated EGFR-mutated, MET-overexpressing advanced NSCLC.29 Oct 2026 · 4 min read
Fact-Checked
BioNTech and DualityBio’s trastuzumab pamirtecan in the DYNASTY-Breast02 phase 3 breast cancer trialClinical TrialsBioNTech and DualityBio Report Modest PFS Gain but Higher ILD in Breast Cancer TrialBioNTech and DualityBio’s phase 3 DYNASTY-Breast02 trial met its primary PFS endpoint for trastuzumab pamirtecan in HR-positive/HER2-low metastatic breast cancer.29 Oct 2026 · 4 min read
Fact-Checked
Page 7 of 149